Clinical Trial Update: Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating switch-maintenance gemcitabine after first-line chemotherapy in malignant pleural mesothelioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma

Drugs mentioned

• Gemcitabine (Gemzar) (gemcitabine)

Snippet

Sponsor: Ain Shams University | Conditions: Malignant Pleural Mesothelioma | Phase 2 | Status: COMPLETED